雷珠单抗联合激光治疗多发性中心性浆液性脉络膜视网膜病变临床观察

doi:10. 13281/j. cnki. issn.1004-4469. 2016. 01. 012

眼科

雷珠单抗联合激光治疗多发性中心性浆液性脉络膜视网膜病变临床观察

张磊刘大川吴航杨慧清

100053首都医科大学宣武医院眼科

收稿日期:2015-10-23 出版日期:2016-01-25 发布日期:2016-01-28
通讯作者: 刘大川，Email：ldc99@sina.com

Clinical observation of efficacy of intravitreal lucentis injection combined with laser treatment for multiple chronic central serous chorioretinopathy

ZHANG Lei, LIU Da-chuan, WU Hang, YANG Hui-qing.

Department of Ophthalmology, Xuanwu Hospital , Capital Medical University, Beijing 100053, China

Received:2015-10-23 Online:2016-01-25 Published:2016-01-28
Contact: LIU Da-chuan，Email：ldc99@sina.com

摘要/Abstract

摘要：

目的观察雷珠单抗玻璃体注射联合眼底氪激光治疗多发性中心性浆液性脉络膜视网膜病变（CSC）的疗效。设计回顾性病例系列。研究对象北京宣武医院多发性CSC患者13例20眼。方法所有患者术前均行最佳矫正视力（BCVA）、荧光素眼底血管造影（FFA）、频域相干光断层扫描（SD-OCT）检查。对患眼先行雷珠单抗玻璃体注射，4周后行眼底氪激光治疗，观察患眼联合治疗后4、8、12周的BCVA，视网膜下液（SRF）及FFA影像学变化。主要指标 BCVA、FFA、SD-OCT。结果雷珠单抗治疗后4周所有患眼的多个渗漏点的神经上皮或色素上皮脱离均显著好转，BCVA显著提高（从0.47±0.24到0.70±0.16，P=0.042）。治疗前中心凹下SRF为（445±134）μm，雷珠单抗治疗4周为（182±101）μm。联合治疗后8周的SRF为（59±11）μm（P=0.004）。治疗前中心凹外SRF为（409±112）μm，雷珠单抗治疗4周后及联合治疗后8周的SRF分别为（142±87）μm、（50±15）μm（P=0.023）。联合治疗后12周的FFA检查显示未见异常渗漏点。结论玻璃体内注射雷珠单抗联合眼底氪激光治疗多发性CSC具有较好的疗效，雷珠单抗治疗能同时对多个渗漏点起作用，促进视网膜神经上皮和色素上皮下液吸收，缩短治疗时间，显著提高视力，降低激光治疗对视网膜的损伤。（眼科，2016，25： 59-62）

关键词: 多发性中心性浆液性脉络膜视网膜病变, 激光治疗, 雷珠单抗, 抗VEGF治疗

Abstract:

Objective To observe the clinical efficacy of intravitreal lucentis injection combined with Laser treatment in the treatment of multiple chronic central serous chorioretinopathy(CSC). Design Retrospective case series. Participants 20 eyes of 13 patients with multiple CSC were enrolled. Methods All patients were confirmed by best corrected visual acuity (BCVA), fundus fluorescein anglograph (FFA) and spectral domain optical coherence tomography (SD-OCT). All the patients were treated with an intravitreal injection of lucentis, 4 weeks after injection, laser treatment were performed. Patients had follow-up on 4,8,12 weeks after all the treatment. Main Outcome Measures included pre and post treatment changes in BCVA, FFA and subretinal fluid (SRF). Results 4 weeks after the lucentis injection, the nerve epithelium or pigment epithelium detachment was significantly improved in all eyes. All of the patients BCVA were significantly improved (from 0.47±0.24 to 0.70±0.16, P=0.042). The SRF was (445±134) μm before treatment, and it was (182±101) μm after intravitreal lucentis injection treatment 4 weeks. The SRF was (59±11) μm (P=0.004) after 8 weeks combined treatment. The SRF of parafoveal was (409±112) μm before treatment, after 4 weeks lucentis treatment it was (142±87) μm and the SRF was (50±15) μm after 8 weeks combined treatment. The FFA showed no abnormal leakage 12 weeks after all treated. Conclusion Intravitreal lucentis injection combined with laser treatment of multiple CSC has curative effect. Intravitreal lucentis injection treatment can work on leakage points, at the same time, promote the retinal neuroepithelium and pigment epithelium under liquid absorption, shorten the treatment time, improve patients' BCVA, and reduce the retinal damage by laser treatment. (Ophthalmol CHN, 2016, 25: 59-62)

Key words: multiplecentral serous chorioretinopathy, laser treatment, lucentis, anti-VEGF therapy

张磊刘大川吴航杨慧清. 雷珠单抗联合激光治疗多发性中心性浆液性脉络膜视网膜病变临床观察[J]. 眼科, doi: 10. 13281/j. cnki. issn.1004-4469. 2016. 01. 012.

ZHANG Lei, LIU Da-chuan, WU Hang, YANG Hui-qing. . Clinical observation of efficacy of intravitreal lucentis injection combined with laser treatment for multiple chronic central serous chorioretinopathy[J]. Ophthalmology in China, doi: 10. 13281/j. cnki. issn.1004-4469. 2016. 01. 012.

[1]	罗嘉婧段虎成陈瑞吕依洋吕红玲晏世刚孔祥斌. 激光治疗性角膜切削术联合眼表干预治疗复发性角膜上皮糜烂的效果[J]. 眼科, 2023, 32(4): 339-343.
[2]	李毅斌. 抗VEGF时代激光视网膜光凝在视网膜静脉阻塞临床管理中的价值[J]. 眼科, 2022, 31(3): 165-168.
[3]	张熙芳陈蕊苗景鹏齐越邓光达杨帆佘海澄. 雷珠单抗及康柏西普玻璃体注药术后前房反应发生率及影响因素[J]. 眼科, 2021, 30(4): 283-289.
[4]	袁昱王晶晶. 抗VEGF与激光治疗非缺血性视网膜分支静脉阻塞继发黄斑水肿的临床对比研究[J]. 眼科, 2020, 29(3): 209-213.
[5]	周瑞陈娟林思勇. 视网膜分支静脉阻塞继发黄斑水肿玻璃体注射雷珠单抗不同治疗方案的疗效对比[J]. 眼科, 2020, 29(1): 63-67.
[6]	闫淑邵玲杜敏沈策英李琰刘钰晁阳阳杨凯转. 湿性年龄相关性黄斑变性玻璃体注射雷珠单抗治疗一年后视力的影响因素[J]. 眼科, 2019, 28(6): 433-437.
[7]	李毅斌. 抗VEGF时代糖尿病视网膜病变治疗的策略和发展方向[J]. 眼科, 2019, 28(4): 245-248.
[8]	赵明贵张士红孙玉波房克爽游启生. 玻璃体切除手术联合雷珠单抗不同给药方案治疗增生性糖尿病视网膜病变[J]. 眼科, 2019, 28(2): 115-119.
[9]	赵旭丽张娣阳光黄舸. 比较两种方案行玻璃体注射雷珠单抗治疗CRVO继发黄斑水肿[J]. 眼科, 2019, 28(2): 111-114.
[10]	乔春艳邵蕾许欣悦杜秀娟杨晓晗曹凯刘涛. 2002-2016年北京同仁医院新生血管性青光眼原发病因及治疗方式的变化趋势[J]. 眼科, 2019, 28(1): 11-16.
[11]	赵可浩，陆文秀，王文萃，雷红. 改良准分子激光治疗性角膜切削术治疗角膜带状变性手术策略分析[J]. 眼科, 2018, 27(2): 135-140.
[12]	马丹丹，曹凯，肖媛媛，孙镝，李毅斌. 预测视网膜静脉阻塞继发黄斑水肿抗VEGF治疗后视力的形态学指标分析[J]. 眼科, 2018, 27(2): 111-115.
[13]	刘益帆刘冬瑞徐进刘平. 玻璃体注射雷珠单抗治疗老年性黄斑变性黄斑水肿与视网膜静脉阻塞性黄斑水肿的短期疗效观察[J]. 眼科, 2017, 26(2): 120-124.
[14]	胡新苗胡梅黄洲基金玉林. 玻璃体注射雷珠单抗治疗视网膜中央静脉阻塞继发黄斑水肿的短期效果[J]. 眼科, 2017, 26(2): 116-119.
[15]	纪海霞张风高丽琴周海英严伟焦璇熊颖. 视盘毛细血管瘤激光治疗的疗效观察[J]. 眼科, 2015, 24(6): 409-413.

雷珠单抗联合激光治疗多发性中心性浆液性脉络膜视网膜病变临床观察

Clinical observation of efficacy of intravitreal lucentis injection combined with laser treatment for multiple chronic central serous chorioretinopathy

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价